The record
| Class | regenerative |
|---|---|
| Also known as | Protein Transduction Domain-Dishevelled Binding Motif, TAT-CTNNSRSS, CXXC5 inhibitor peptide |
| Chain length | - |
| Molecular weight | 3,082.68 Da |
| Half-life | Not established (topical application) |
| Route | Topical (scalp/skin) |
| Studied for | Androgenetic alopecia (investigational); Wound healing enhancement; Hair follicle regeneration; Scar reduction |
| Research use | Wnt signaling studies; Hair follicle biology; Wound healing mechanisms |
| What has been shown | Promotes hair follicle neogenesis; Accelerates wound healing; Enhances wound-induced hair neogenesis (WIHN); Synergistic effects with valproic acid (VPA) |
| How it works | Chimeric peptide combining HIV TAT-derived protein transduction domain (PTD: RKKRRQRRR) with dishevelled binding motif (DBM: CTNNSRSS) that interferes with CXXC5-Dvl interaction. Disrupts negative feedback on Wnt/β-catenin signaling, promoting activation. Enhances wound healing, hair follicle neogenesis (WIHN), and tissue regeneration. PTD enables cellular penetration while DBM blocks CXXC5, a neg |
| Patent status | patented (Yonsei University, South Korea) |
| Regulatory status | research/cosmetic |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Joint / Tendon Healing (affection, 37%)
- Wound Healing / Tissue Repair (affection, 40%)
- Skin Regeneration / Aesthetic Healing (affection, 54%)
- Bone Health / Remodeling Support (affection, 40%)
- Androgenetic alopecia (illness, 100%)
- Hair follicle regeneration (illness, 100%)
- Scar reduction (illness, 100%)
- Wound healing enhancement (illness, 100%)
- Slow healing of an injury (symptom, 50%)
- Muscle loss or weakness (symptom, 33%)
- Skin ageing or thinning (symptom, 50%)